Mallinckrodt Receives US Patent Covering Release Profile Of Xartemis XR
Mallinckrodt has been granted a patent from the US PTO which contains composition claims directed to unique design, formulation, pharmacokinetic, and release characteristics of Xartemis XR (oxycodone hydrochloride+acetaminophen).
Xartemis XR (formerly known as MNK-795), a key driver in Mallinckrodt's near-term pipeline, is an investigational extended-release oral formulation of oxycodone and acetaminophen that has been studied with twice-daily dosing for the management of acute pain in a post-surgical model. If approved, Xartemis XR will be the first oxycodone and acetaminophen combination medication specifically designed with immediate- and extended-release components. The patent, US Patent No. 8,658,631, was issued on February 25.
The release profile of Xartemis XR combines Mallinckrodt-proprietary technology and Depomed's advanced Acuform drug-delivery technology. Between the Mallinckrodt and Depomed patent families, Mallinckrodt believes Xartemis XR will have strong patent protection for its novel features.